We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| 2.98 | 1.85% | 163.79 | 164.25 | 160.74 | 161.85 | 5,850,104 | 01:00:00 |
From Nov 2023 to May 2024
9:57 ET--AbbVie is one of the most mentioned companies in the U.S. across all news items in the last 12 hours, according to Factiva data. AbbVie will acquire neuroscience-drug maker Cerevel Therapeutics for $45 a share, giving the company an equity value of about $8.7 billion. The deal is AbbVie's second major acquisition in the last two weeks, after the pharmaceutical giant said Nov. 30 it would acquire ImmunoGen for $10 billion. Cerevel is developing potential candidates to treat schizophrenia, Parkinson's disease and mood disorders. AbbVie said the deal complements its existing neuroscience portfolio. Dow Jones & Co. owns Factiva. (chris.wack@wsj.com)
(END) Dow Jones Newswires
December 07, 2023 10:12 ET (15:12 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
